InvestorsHub Logo
Followers 74
Posts 10289
Boards Moderated 1
Alias Born 11/22/2004

Re: None

Wednesday, 08/30/2023 1:13:27 PM

Wednesday, August 30, 2023 1:13:27 PM

Post# of 644754
OTLK is way oversold on news. Under .25 and target at $1, "Cantor Fitzgerald analyst Kristen Kluska downgrades Outlook Therapeutics (NASDAQ:OTLK) from Overweight to Neutral and lowers the price target from $4.5 to $1."

Rayank

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.